Brolucizumab-Associated Ocular Complications with Concomitant Sub-Tenon Triamcinolone Acetonide: A Multicenter Retrospective Study
Journal of Clinical Medicine · 02.11.2026 · 15 (21) · 8507
DOI: 10.3390/jcm15218507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.11.2026. Verfasst von Ryo Ando und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Brolucizumab is a potent therapeutic option for neovascular age-related macular degeneration (nAMD), but carries risks of intraocular inflammation (IOI), retinal vasculitis (RV), and retinal vascular occlusion (RO). This study evaluated the occurrence of these adverse events in eyes treated with intravitreal brolucizumab injection (IVBr) under a treatment strategy incorporating sub-Tenon injection of triamcinolone acetonide (STTA).
Methods
This multicenter retrospective study included patients with nAMD who initiated IVBr treatment with STTA and were followed for at least 1 month. IVBr was administered under a treatment strategy incorporating STTA, with repeat STTA when more than 3 months had elapsed since the previous STTA.
Results
The study included 80 eyes of 80 patients (59 men and 21 women; mean age, 74.5 ± 7.7 years) from 9 institutions. The mean number of previous intravitreal anti-vascular endothelial growth factor injections was 20.4 ± 18.3. The mean follow-up period was 6.8 ± 4.8 months. The mean numbers of IVBr and STTA administrations were 2.6 ± 1.6 and 1.7 ± 1.0 per eye, respectively. Three eyes (3.75%) developed adverse events: one developed IOI, one developed IOI with RV, and one developed RO without IOI or RV.
Conclusions
IOI, RV, and RO occurred in 2.5%, 1.25%, and 1.25% of eyes, respectively. These data may help inform the design and sample-size planning of future prospective comparative studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
- Department of Ophthalmology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
- Department of Ophthalmology, Nishida Hospital, Saiki 876-0047, Japan.
- Department of Ophthalmology, Oita University Faculty of Medicine, Yufu 879-5593, Japan.
- Hikichi Eye Clinic, Sapporo 060-0807, Japan.
- Department of Ophthalmology, Yayoi Hospital, Toyohashi 441-8106, Japan.
ORCID-Profile: Ryo Ando, Aki Kato, Hisashi Matsubara
Zitieren
APA
Ando, R., Kato, A., Kimoto, K., Itotani, M., Hikichi, T., Watanabe, G., Sato, T., Matsuda, H., Shiose, S., Matsubara, H., & Ishida, S. (2026). Brolucizumab-Associated Ocular Complications with Concomitant Sub-Tenon Triamcinolone Acetonide: A Multicenter Retrospective Study. Journal of Clinical Medicine, 15(21), 8507. https://doi.org/10.3390/jcm15218507
Vancouver
Ando R, Kato A, Kimoto K, Itotani M, Hikichi T, Watanabe G, et al. Brolucizumab-Associated Ocular Complications with Concomitant Sub-Tenon Triamcinolone Acetonide: A Multicenter Retrospective Study. Journal of Clinical Medicine. 2026;15(21):8507. doi:10.3390/jcm15218507
BibTeX
@article{Ando2026,
author = {Ando, Ryo and Kato, Aki and Kimoto, Kenichi and Itotani, Maho and Hikichi, Taiichi and Watanabe, Goro and Sato, Taku and Matsuda, Hideho and Shiose, Satomi and Matsubara, Hisashi and Ishida, Susumu},
title = {Brolucizumab-Associated Ocular Complications with Concomitant Sub-Tenon Triamcinolone Acetonide: A Multicenter Retrospective Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8507},
doi = {10.3390/jcm15218507}
}
EUVIMED